Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $141.5 million.

  • Agios Pharmaceuticals' Operating Expenses rose 425.58% to $141.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $526.2 million, marking a year-over-year increase of 1382.95%. This contributed to the annual value of $526.2 million for FY2025, which is 1382.95% up from last year.
  • Agios Pharmaceuticals' Operating Expenses amounted to $141.5 million in Q4 2025, which was up 425.58% from $129.7 million recorded in Q3 2025.
  • In the past 5 years, Agios Pharmaceuticals' Operating Expenses ranged from a high of $141.5 million in Q4 2025 and a low of $91.2 million during Q3 2021
  • In the last 5 years, Agios Pharmaceuticals' Operating Expenses had a median value of $104.2 million in 2021 and averaged $109.4 million.
  • Within the past 5 years, the most significant YoY rise in Agios Pharmaceuticals' Operating Expenses was 32327.37% (2021), while the steepest drop was 2998.93% (2021).
  • Agios Pharmaceuticals' Operating Expenses (Quarter) stood at $104.8 million in 2021, then fell by 1.28% to $103.5 million in 2022, then rose by 9.56% to $113.4 million in 2023, then grew by 19.75% to $135.8 million in 2024, then grew by 4.26% to $141.5 million in 2025.
  • Its Operating Expenses stands at $141.5 million for Q4 2025, versus $129.7 million for Q3 2025 and $139.5 million for Q2 2025.